Nortrel 7/7/7 — Class III drug recall D-0322-2024
Ongoing recall by Teva Pharmaceuticals USA, Inc, reported 2024-02-21, distributed nationwide. Discoloration: discolored tablets (shades of blue) mixed in with the white inert remainder tablets.
| Recall number | D-0322-2024 |
|---|---|
| Product type | Drug |
| Classification | Class III |
| Status | Ongoing |
| Voluntary or mandated | Voluntary |
| Recalling firm | Teva Pharmaceuticals USA, Inc, Parsippany, NJ, United States |
| Recall initiated | 2024-01-25 |
| Classified | 2024-02-12 |
| Reported by FDA | 2024-02-21 |
| Distributed | Nationwide (US) |
| Quantity | 19,824 cartons |
| NDC | 00555-9012, 00555-9012-58, 00555-9012-79 |
| Lot numbers | 100040731 |
| Expiration dates | 2024-07-31 |
Product
Nortrel 7/7/7 (norethindrone and ethinyl estradiol tablets USP- triphasic regimen), packaged in cartons, each carton contains 6 blister cards, each card contains 28 tablets, Rx only, TEVA PHARMACEUTICALS USA, INC., North Wales, PA 19454, NDC 0555-9012-58
Reason for recall
Discoloration: discolored tablets (shades of blue) mixed in with the white inert remainder tablets.
Machine access
This record, with every extracted code, the verbatim FDA record and provenance, is available from the recall API: GET https://api.data.aroqon.com/v1/recalls/D-0322-2024. Look up any UPC, UDI, NDC or lot with /v1/recalls/lookup?code=…. API docs · free and paid keys.
Source: U.S. Food and Drug Administration enforcement report via openFDA (CC0). Structured by Data Foundry (recall-structuring@2); last changed 2026-09-26. Not affiliated with or endorsed by FDA. Not medical or legal advice.